The Landscape of Immunotherapy Resistance in NSCLC

Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) or acquired resistance remains a challenge. Criteria for a uniform clinical definition of acquired resistance have been r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Daniele Frisone, Alex Friedlaender, Alfredo Addeo, Petros Tsantoulis
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2022-04-01
Reeks:Frontiers in Oncology
Onderwerpen:
immunotherapy
resistance
checkpoint inhibitor
NSCLC
lung cancer
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2022.817548/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items